4142:TPE
Adimmune Corp
17,90 TWD
arrow_upward
+0,56%(+0,10) 1J
21 oct., 13:30:30 UTC+8 · TWD
search
Tous les symboles
| Symbole | Cours | Variation | % variat. |
|---|
insights_autoGénération des principaux insights pour 4142...
Ouverture
18,00 TWD
Élevé
18,05 TWD
Faible
17,85 TWD
Cap. boursière
7,69 Md
Vol. moyen
1,06 M
Volume
367,00 k
+ haut sur 1 an
22,50 TWD
+ bas sur 1 an
16,40 TWD
BPA
-0,34 TWD
Actions en circulation
235,29 M
Nombre d'employés
564
Ouverture
18,00 TWD
Élevé
18,05 TWD
Faible
17,85 TWD
Cap. boursière
7,69 Md
Vol. moyen
1,06 M
Volume
367,00 k
+ haut sur 1 an
22,50 TWD
+ bas sur 1 an
16,40 TWD
BPA
-0,34 TWD
Actions en circulation
235,29 M
Nombre d'employés
564
Articles
Sources : Web et partenaires du secteur de l'information
Bourse Direct
·
il y a 1 heure
Wall Street progresse, mais à tâtons
BeInCrypto
·
il y a 6 heures
Le Bitcoin est-il sur le point d'une correction plus profonde ? Le S&P 500 pourrait détenir la réponse
ABC Bourse
·
il y a 2 heures
S&P 500 - Les actions à suivre mercredi: Super Micro, SpaceX, Tesla, Netflix, AT
Investing.com France
·
il y a 12 heures
Le Dow Jones porté par 3M et la santé avant une autre salve de résultats T3
Profil
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
À propos de Adimmune Corp